{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:06:10Z","timestamp":1781517970358,"version":"3.54.1"},"reference-count":126,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education","award":["2021R1F1A1048113"],"award-info":[{"award-number":["2021R1F1A1048113"]}]},{"name":"Ministry of Education","award":["2021R1I1A1A01059868"],"award-info":[{"award-number":["2021R1I1A1A01059868"]}]},{"name":"Ministry of Education","award":["2022-0-00621"],"award-info":[{"award-number":["2022-0-00621"]}]},{"name":"Ministry of Education","award":["HI22C073600"],"award-info":[{"award-number":["HI22C073600"]}]},{"name":"Institute of Information &amp; Communications Technology Planning &amp; Evaluation (IITP) grant funded by the Korea government (MSIT)","award":["2021R1F1A1048113"],"award-info":[{"award-number":["2021R1F1A1048113"]}]},{"name":"Institute of Information &amp; Communications Technology Planning &amp; Evaluation (IITP) grant funded by the Korea government (MSIT)","award":["2021R1I1A1A01059868"],"award-info":[{"award-number":["2021R1I1A1A01059868"]}]},{"name":"Institute of Information &amp; Communications Technology Planning &amp; Evaluation (IITP) grant funded by the Korea government (MSIT)","award":["2022-0-00621"],"award-info":[{"award-number":["2022-0-00621"]}]},{"name":"Institute of Information &amp; Communications Technology Planning &amp; Evaluation (IITP) grant funded by the Korea government (MSIT)","award":["HI22C073600"],"award-info":[{"award-number":["HI22C073600"]}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["2021R1F1A1048113"],"award-info":[{"award-number":["2021R1F1A1048113"]}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["2021R1I1A1A01059868"],"award-info":[{"award-number":["2021R1I1A1A01059868"]}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["2022-0-00621"],"award-info":[{"award-number":["2022-0-00621"]}]},{"name":"Ministry of Health &amp; Welfare, Republic of Korea","award":["HI22C073600"],"award-info":[{"award-number":["HI22C073600"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Dyslipidemia is a major risk factor for stroke, following hypertension, diabetes, and smoking, and is an important risk factor for the prevention and treatment of coronary artery disease and peripheral vascular disease, including stroke. Recent guidelines recommend considering low-density lipoprotein cholesterol (LDL-C)-lowering therapies, such as statins (preferably), ezetimibe, or proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors to prevent the occurrence or recurrence of stroke, adhering to the \u201clower is better\u201d approach. In this review, we examined the evidence supporting lipid-lowering medications like statins, ezetimibe, and PCSK9 inhibitors for secondary stroke prevention and dyslipidemia management in different stroke subtypes. Stroke guidelines advocate for administering the maximum tolerable dose of statins as the primary treatment and as soon as possible despite the potential for new-onset diabetes mellitus and possible muscle and liver toxicity due to their demonstrated benefits in secondary prevention of cardiovascular diseases and mortality reduction. When statin use is insufficient for LDL lowering, ezetimibe and PCSK9 inhibitors are recommended as complementary therapies. It is essential to establish lipid-lowering therapy goals based on the stroke subtype and the presence of comorbidities.<\/jats:p>","DOI":"10.3390\/medicina59040776","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T03:14:09Z","timestamp":1681701249000},"page":"776","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-2278","authenticated-orcid":false,"given":"Yoonkyung","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Neurology, Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soojeong","family":"Eom","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjeong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-762X","authenticated-orcid":false,"given":"Tae-Jin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Neurology, Seoul Hospital, College of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/STROKEAHA.116.014377","article-title":"Declining Incidence of Ischemic Stroke: What Is the Impact of Changing Risk Factors? The Troms\u00f8 Study 1995 to 2012","volume":"48","author":"Wilsgaard","year":"2017","journal-title":"Stroke"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management","volume":"72","author":"Ganda","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.25432","article-title":"Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population","volume":"85","author":"Varbo","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9883352","DOI":"10.1155\/2021\/9883352","article-title":"Current Management Guidelines on Hyperlipidemia: The Silent Killer","volume":"2021","author":"Su","year":"2021","journal-title":"J. Lipids."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration (2010). LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/01.wnl.0000254472.41810.0d","article-title":"Lipid levels and the risk of ischemic stroke in women","volume":"68","author":"Kurth","year":"2007","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/STROKEAHA.117.019653","article-title":"Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study","volume":"49","author":"Hindy","year":"2018","journal-title":"Stroke"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3988\/jcn.2021.17.1.86","article-title":"Reassessment of Inclusion Criteria in the 2013 the American College of Cardiology and the American Heart Association Cholesterol Guidelines for Cardiovascular Disease Prevention","volume":"17","author":"Lee","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5853\/jos.2021.01249","article-title":"Role of Blood Lipid Levels and Lipid-Lowering Therapy in Stroke Patients with Different Levels of Cerebral Artery Diseases: Reconsidering Recent Stroke Guidelines","volume":"23","author":"Kim","year":"2021","journal-title":"J. Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1747493019873594","article-title":"Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview","volume":"15","author":"Milionis","year":"2020","journal-title":"Int. J. Stroke"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tramacere, I., Boncoraglio, G.B., Banzi, R., Del Giovane, C., Kwag, K.H., Squizzato, A., and Moja, L. (2019). Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: A systematic review and network meta-analysis. BMC Med., 17.","DOI":"10.1186\/s12916-019-1298-5"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/jc.2018-00470","article-title":"Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol","volume":"103","author":"Nichols","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_19","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"ref_20","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","article-title":"Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1161\/CIR.0000000000000626","article-title":"Systematic Review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Wilson","year":"2019","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: A meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3904\/kjim.2019.188","article-title":"2018 Guidelines for the management of dyslipidemia FAU","volume":"34","author":"Rhee","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"Iii39","DOI":"10.1161\/01.CIR.0000131517.20177.5a","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2019.01.006","article-title":"Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis","volume":"282","author":"Malhotra","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/STROKEAHA.107.501700","article-title":"Effect of pretreatment with statins on ischemic stroke outcomes","volume":"39","author":"Reeves","year":"2008","journal-title":"Stroke"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5853\/jos.2015.01578","article-title":"Effect and Safety of Rosuvastatin in Acute Ischemic Stroke","volume":"18","author":"Heo","year":"2016","journal-title":"J. Stroke"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1161\/STROKEAHA.116.014600","article-title":"Combination of Thrombolysis and Statins in Acute Stroke Is Safe","volume":"47","author":"Montaner","year":"2016","journal-title":"Stroke"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5853\/jos.2017.00836","article-title":"Early Statins after Intravenous or Endovascular Recanalization Is Beneficial Regardless of Timing, Intensity, and Stroke Mechanism","volume":"19","author":"Jeong","year":"2017","journal-title":"J. Stroke"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kang, J., Kim, N., Park, T.H., Bang, O.Y., Lee, J.S., Lee, J., Han, M.K., Park, S.H., Gorelick, P.B., and Bae, H.J. (2015). Early statin use in ischemic stroke patients treated with recanalization therapy: Retrospective observational study. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0367-4"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Choi, J.C., Lee, J.S., Park, T.H., Cho, Y.J., Park, J.M., Kang, K., Lee, K.B., Lee, S.J., Ko, Y., and Lee, J. (2015). Effect of pre-stroke statin use on stroke severity and early functional recovery: A retrospective cohort study. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0376-3"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke","volume":"382","author":"Amarenco","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1984","DOI":"10.1212\/WNL.0000000000009397","article-title":"Statin therapy in acute cardioembolic stroke with no guidance-based indication","volume":"94","author":"Park","year":"2020","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: Perception vs. the evidence-focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells","volume":"126","author":"Yada","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/CIRCULATIONAHA.112.122135","article-title":"Statins and Risk of New-Onset Diabetes Mellitus","volume":"126","author":"Shah","year":"2012","journal-title":"Circulation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2310\/JIM.0b013e318197ec8b","article-title":"Effect of Statins on Fasting Plasma Glucose in Diabetic and Nondiabetic Patients","volume":"57","author":"Sukhija","year":"2009","journal-title":"J. Investig. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1464-5491.2011.03553.x","article-title":"Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes\u2014The CORALL study","volume":"29","author":"Simsek","year":"2012","journal-title":"Diabet. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.diabres.2009.10.008","article-title":"Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis","volume":"87","author":"Baker","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"n1537","DOI":"10.1136\/bmj.n1537","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: Systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1734-1140(11)70601-6","article-title":"Statin-induced myopathies","volume":"63","author":"Tomaszewski","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations","volume":"14","author":"Milisenda","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Jacobsen","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Clarke, A.T., Johnson, P.C., Hall, G.C., Ford, I., and Mills, P.R. (2016). High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151587"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622316672544","article-title":"Ezetimibe: An update on its clinical usefulness in specific patient groups","volume":"8","author":"Hammersley","year":"2017","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients with Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.17340\/jkna.2022.3.1","article-title":"Management of Dyslipidemia after Stroke","volume":"40","author":"Chang","year":"2022","journal-title":"J Korean Neurol. Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7326\/0003-4819-140-8-200404200-00034","article-title":"Ezetimibe and statin-associated myopathy","volume":"140","author":"Fux","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0828-282X(06)70253-7","article-title":"Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"22","author":"Simard","year":"2006","journal-title":"Can. J. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0195-668X(02)00807-2","article-title":"Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia","volume":"24","author":"Knopp","year":"2003","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.3748\/wjg.14.5098","article-title":"Serious drug-induced liver disease secondary to ezetimibe","volume":"14","author":"Castellote","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: A new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMe1813758","article-title":"PCSK9-A Journey to Cardiovascular Outcomes","volume":"379","author":"Burnett","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMe1703138","article-title":"PCSK9 Inhibition to Reduce Cardiovascular Events","volume":"376","author":"Dullaart","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/dom.13599","article-title":"PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes","volume":"21","author":"Monami","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years from the Open-Label OSLER-1 Extension Study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2018.07.017","article-title":"Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial","volume":"276","author":"Taskinen","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4314\/ahs.v19i2.36","article-title":"Modifiable and non-modifiable risk factors in ischemic stroke: A meta-analysis","volume":"19","author":"Cui","year":"2019","journal-title":"Afr. Health Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1161\/STROKEAHA.119.026402","article-title":"Association of Lipids With Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study Among 267,500 Chinese","volume":"50","author":"Gu","year":"2019","journal-title":"Stroke"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41591-019-0366-x","article-title":"Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults","volume":"25","author":"Sun","year":"2019","journal-title":"Nat. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2018.04.050","article-title":"Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease","volume":"72","author":"Saeed","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.003","article-title":"Metabolic Syndrome in Polish Ischemic Stroke Patients","volume":"24","author":"Brola","year":"2015","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"103","author":"Davenport","year":"2001","journal-title":"Circulation"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5853\/jos.2015.17.2.168","article-title":"Low Plasma Proportion of Omega 3-Polyunsaturated Fatty Acids Predicts Poor Outcome in Acute Non-Cardiogenic Ischemic Stroke Patients","volume":"17","author":"Song","year":"2015","journal-title":"J. Stroke"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.nutres.2015.04.008","article-title":"Low levels of plasma omega 3-polyunsaturated fatty acids are associated with cerebral small vessel diseases in acute ischemic stroke patients","volume":"35","author":"Song","year":"2015","journal-title":"Nutr. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3c","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","article-title":"Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention","volume":"8","author":"Amarenco","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1161\/STROKEAHA.121.034576","article-title":"Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors","volume":"52","author":"Saver","year":"2021","journal-title":"Stroke"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/STROKEAHA.108.534107","article-title":"Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes","volume":"40","author":"Amarenco","year":"2009","journal-title":"Stroke"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1212\/01.wnl.0000296277.63350.77","article-title":"Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"70","author":"Goldstein","year":"2008","journal-title":"Neurology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/STROKEAHA.117.017343","article-title":"Statin Adherence Is Associated with Reduced Recurrent Stroke Risk in Patients with or without Atrial Fibrillation","volume":"48","author":"Flint","year":"2017","journal-title":"Stroke"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.amjcard.2016.12.031","article-title":"Relation of Low-Density Lipoprotein Cholesterol to Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation","volume":"119","author":"Qi","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2007.09.063","article-title":"Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials","volume":"51","author":"Fauchier","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2125.2012.04258.x","article-title":"The role of statin therapy in the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials","volume":"74","author":"Fang","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_95","first-page":"422","article-title":"Does preoperative statin therapy prevent postoperative atrial fibrillation in patients undergoing cardiac surgery?","volume":"20","author":"Goh","year":"2015","journal-title":"Interdiscip. CardioVascular Thorac. Surgery"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e013941","DOI":"10.1161\/JAHA.119.013941","article-title":"Effect of Statin Therapy on Outcomes of Patients with Acute Ischemic Stroke and Atrial Fibrillation","volume":"8","author":"Choi","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40263-021-00829-6","article-title":"The Effect of Statin Treatment on Outcomes of Cardioembolic Stroke: A Systematic Review and Meta-Analysis of Real-World Studies","volume":"35","author":"Xu","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/STROKEAHA.117.020031","article-title":"Distribution and Temporal Trends from 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis","volume":"49","author":"Ornello","year":"2018","journal-title":"Stroke"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1056\/NEJMc1609156","article-title":"Cryptogenic Stroke","volume":"375","author":"Saver","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMoa1412981","article-title":"One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke","volume":"374","author":"Amarenco","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMoa1802712","article-title":"Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke","volume":"378","author":"Amarenco","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archneurol.2010.349","article-title":"Statins after intracerebral hemorrhage: To treat or not to treat","volume":"68","author":"Goldstein","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","author":"Collins","year":"2004","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/CIRCULATIONAHA.111.055269","article-title":"Statins and intracerebral hemorrhage: Collaborative systematic review and meta-analysis","volume":"124","author":"Hackam","year":"2011","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.112.655894","article-title":"Statin therapy and the risk of intracerebral hemorrhage: A meta-analysis of 31 randomized controlled trials","volume":"43","author":"McKinney","year":"2012","journal-title":"Stroke"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/archneurol.2010.356","article-title":"Statin use following intracerebral hemorrhage: A decision analysis","volume":"68","author":"Westover","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1001\/jamaneurol.2014.2124","article-title":"Effect of statin use during hospitalization for intracerebral hemorrhage on mortality and discharge disposition","volume":"71","author":"Flint","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10143-012-0431-0","article-title":"Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage","volume":"36","author":"Rupa","year":"2013","journal-title":"Neurosurg. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.56.6.773","article-title":"Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage","volume":"56","author":"Bailey","year":"2001","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/STROKEAHA.118.024449","article-title":"Five-Year Risk of Major Ischemic and Hemorrhagic Events After Intracerebral Hemorrhage","volume":"50","author":"Casolla","year":"2019","journal-title":"Stroke"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","article-title":"Long-term prognosis after intracerebral haemorrhage: Systematic review and meta-analysis","volume":"85","author":"Poon","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/jnnp.2006.106500","article-title":"The risk of recurrent stroke after intracerebral haemorrhage","volume":"78","author":"Hanger","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1440-1681.1999.03081.x","article-title":"Hypertension mechanisms causing stroke","volume":"26","author":"Johansson","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/01.STR.25.8.1605","article-title":"Hypertension and risk of stroke recurrence","volume":"25","author":"Alter","year":"1994","journal-title":"Stroke"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0002-9149(76)90357-X","article-title":"Role of hypertension in atherosclerosis and cardiovascular disease","volume":"38","author":"Hollander","year":"1976","journal-title":"Am. J. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2002). MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 360, 7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus without Diabetes Mellitus: Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial","volume":"3","author":"Anzalone","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis","volume":"111","author":"Ambrose","year":"2005","journal-title":"Circulation"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/nep.12320","article-title":"KHA-CARI commentary on the KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"19","author":"Palmer","year":"2014","journal-title":"Nephrology"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3988\/jcn.2014.10.3.222","article-title":"Distribution of cerebral microbleeds determines their association with impaired kidney function","volume":"10","author":"Song","year":"2014","journal-title":"J. Clin. Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/776\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:17:01Z","timestamp":1760123821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":126,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["medicina59040776"],"URL":"https:\/\/doi.org\/10.3390\/medicina59040776","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]}}}